Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.
OBJECTIVE
Women at high risk of breast cancer face the complex decision of whether to take tamoxifen or raloxifene for breast cancer chemoprevention. We investigated what is known about decisions of women regarding chemoprevention.


METHODS
Using MEDLINE, CINAHL, and PSYCINFO, plus reviewing reference lists of relevant articles, in December 2009 we identified 13 studies that addressed patient decisions about breast cancer chemoprevention, were published in 1995 or later, were peer-reviewed primary clinical studies, and reported rates at which participants showed interest in (hypothetical uptake) or accepted (real uptake) chemoprevention medications.


RESULTS
Nine studies provided information about hypothetical breast cancer chemoprevention decisions (mean uptake rate, 24.7%) and five provided information about real decisions (mean uptake rate, 14.8%). The range of rates was wide, and each of the hypothetical uptake studies assessed interest differently. A logistic regression model found significant correlation with uptake of decision type (hypothetical versus real, odds ratio [OR] = 1.65; 95% CI, 1.26 to 2.16), educational or decision support intervention (provided v not, OR = 0.21; 95% CI, 0.17 to 0.27), and cohort risk for breast cancer (high-risk v general population, OR = 0.65; 95% CI, 0.56 to 0.75). Perceived vulnerability to breast cancer was consistently correlated with increased uptake, and concern for adverse effects was correlated with reduced uptake. All studies used a correlational/descriptive design, and most studies used convenience sampling strategies.


CONCLUSIONS
Breast cancer chemoprevention uptake rates are low and variation is wide. Hypothetical uptake rates are higher than real uptake, and interventions markedly reduce uptake. Research is needed that uses reproducible sampling methods and examines decision support strategies that lead to quality decisions.
Ropka
Mary E
ME
Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA 22908, USA. mer2e@virginia.edu
Keim
Jess
J
Philbrick
John T
JT
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D003657:Decision Making; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D015201:Meta-Analysis as Topic
D000970:Antineoplastic Agents
Breast Cancer Res Treat. 2010 Feb;119(3):613-20
19908143
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):840-55
16702359
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
J Clin Oncol. 2004 Dec 15;22(24):4951-7
15598980
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):162-6
16434605
JAMA. 2000 Apr 19;283(15):2008-12
10789670
J Clin Oncol. 2009 Jul 1;27(19):3235-58
19470930
Arch Intern Med. 2001 Jul 9;161(13):1639-44
11434796
JAMA. 2006 Jun 21;295(23):2727-41
16754727
Breast Cancer Res Treat. 2008 Apr;108(3):435-53
17554628
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
19622511
Ethn Dis. 2005 Summer;15(3):365-72
16108294
Ann Surg Oncol. 2001 Aug;8(7):580-5
11508619
J Natl Cancer Inst. 2003 Apr 16;95(8):570-1
12697842
Breast Cancer Res Treat. 2007 Jan;101(1):95-104
17033928
Psychooncology. 2001 Nov-Dec;10(6):521-33
11747064
Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1032-4
17507634
Arch Intern Med. 2006 Nov 13;166(20):2260-5
17101945
J Clin Oncol. 1999 Jun;17(6):1939-55
10561236
J Womens Health (Larchmt). 2003 Oct;12(8):769-78
14588127
Breast Cancer Res Treat. 2005 Nov;94(2):153-9
16261414
Ann N Y Acad Sci. 2001 Dec;949:286-91
11795364
Cancer. 2005 May 15;103(10):1996-2005
15825209
J Gen Intern Med. 2006 Jul;21(7):779-85
16808782
Cancer. 2005 Jan 1;103(1):209-10
15540238
J Natl Cancer Inst. 2003 Apr 2;95(7):526-32
12671020
J Natl Compr Canc Netw. 2009 Nov;7(10):1060-96
19930975
Health Aff (Millwood). 2004;Suppl Variation:VAR63-72
15471770
BMJ. 2003 Sep 27;327(7417):736-40
14512487
Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46
19686352
Nat Clin Pract Oncol. 2006 Oct;3(10):523
17019426
Cancer. 2001 Aug 15;92(4):959-68
11550171
Evid Rep Technol Assess (Summ). 2002 Mar;(47):1-11
11979732
Soc Sci Med. 2004 Apr;58(7):1427-42
14759687
BMC Med Res Methodol. 2004 Dec 10;4(1):27
15588327
Can Fam Physician. 2006 May;52:624-5
17327893
Med Care. 2008 Sep;46(9):946-53
18725849
Br J Surg. 2000 Nov;87(11):1448-54
11091231
BMJ. 2002 Oct 26;325(7370):961-4
12399352
Genet Med. 2007 Nov;9(11):727-38
18007141
Ann Fam Med. 2005 May-Jun;3(3):242-7
15928228
Ann Intern Med. 2002 Jul 2;137(1):52-4
12093247
Br J Health Psychol. 2007 Sep;12(Pt 3):383-401
17640453
Am J Prev Med. 2004 Jan;26(1):67-80
14700715
J Clin Epidemiol. 2004 Jul;57(7):698-711
15358397